MA32611B1 - Procedes de traitement de la thalassemie - Google Patents

Procedes de traitement de la thalassemie

Info

Publication number
MA32611B1
MA32611B1 MA33672A MA33672A MA32611B1 MA 32611 B1 MA32611 B1 MA 32611B1 MA 33672 A MA33672 A MA 33672A MA 33672 A MA33672 A MA 33672A MA 32611 B1 MA32611 B1 MA 32611B1
Authority
MA
Morocco
Prior art keywords
thalassemia
operations
treatment
therapeutic amount
effective therapeutic
Prior art date
Application number
MA33672A
Other languages
Arabic (ar)
English (en)
Inventor
John D Hood
Original Assignee
Targegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41581108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32611(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targegen Inc filed Critical Targegen Inc
Publication of MA32611B1 publication Critical patent/MA32611B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement, d'amélioration ou de retardement d'au moins un symptôme d'une affection génétique du sang, par exemple une affection liée aux drépanocytes ou une thalassémie, chez un patient le nécessitant, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de jak2. Elle concerne également en partie un procédé de réduction d'une splénomégalie chez un patient souffrant de thalassémie, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de jak2.
MA33672A 2008-08-05 2011-03-04 Procedes de traitement de la thalassemie MA32611B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8623308P 2008-08-05 2008-08-05
PCT/US2009/052544 WO2010017122A2 (fr) 2008-08-05 2009-08-03 Procédés de traitement de la thalassémie

Publications (1)

Publication Number Publication Date
MA32611B1 true MA32611B1 (fr) 2011-09-01

Family

ID=41581108

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33672A MA32611B1 (fr) 2008-08-05 2011-03-04 Procedes de traitement de la thalassemie

Country Status (20)

Country Link
US (1) US20110269721A1 (fr)
EP (1) EP2355827A2 (fr)
JP (1) JP2011530517A (fr)
KR (1) KR20110053347A (fr)
CN (1) CN102112131A (fr)
AU (1) AU2009279825A1 (fr)
BR (1) BRPI0917575A2 (fr)
CA (1) CA2732791A1 (fr)
CL (1) CL2011000242A1 (fr)
CO (1) CO6351728A2 (fr)
CR (1) CR20110115A (fr)
DO (1) DOP2011000044A (fr)
EC (1) ECSP11010847A (fr)
IL (1) IL211061A0 (fr)
MA (1) MA32611B1 (fr)
MX (1) MX2011001426A (fr)
NI (1) NI201100031A (fr)
RU (1) RU2011108563A (fr)
SV (1) SV2011003823A (fr)
WO (1) WO2010017122A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006139258A (ru) 2004-04-08 2008-05-20 Таргеджен, Инк. (US) Бензотриазиновые ингибиторы киназ
EP1799656A4 (fr) 2004-08-25 2009-09-02 Targegen Inc Composes heterocycliques et methodes d'utilisation
BR122021011788B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
CA2816957A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procedes de traitement de la myelofibrose
CA2819560A1 (fr) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Traitement d'affections mediees par jak2
WO2013013188A1 (fr) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Inhibiteurs de protéine kinase hétérocycliques
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN103664799A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
AU2014236820B2 (en) * 2013-03-14 2018-08-02 Sumitomo Pharma Oncology, Inc. JAK2 and ALK2 inhibitors and methods for their use
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
FI3442947T3 (fi) * 2016-04-15 2023-08-24 Epizyme Inc Amiinisubstituoituja aryyli- tai heteroaryyliyhdisteitä EHMT1- ja EHMT2-inhibiittoreina
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
EA202090955A1 (ru) * 2017-10-18 2020-11-27 Эпизайм, Инк. Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
CA3096984A1 (fr) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de kinases axl et leur utilisation
CA3095580A1 (fr) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de kinase pim pour le traitement de neoplasmes myeloproliferatifs et de fibrose associee au cancer
WO2020023910A1 (fr) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Procédés de traitement de maladies associées à l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destinés à être utilisés dans ceux-ci
US20210355088A1 (en) * 2018-09-07 2021-11-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
EP3924351A4 (fr) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
CN112778282B (zh) * 2021-01-06 2022-07-22 温州医科大学 一种嘧啶类小分子化合物及其应用
WO2024097653A1 (fr) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Inhibiteur de pim-1 pour le traitement de néoplasmes myéloprolifératifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021011788B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica

Also Published As

Publication number Publication date
IL211061A0 (en) 2011-04-28
WO2010017122A3 (fr) 2010-04-08
ECSP11010847A (es) 2011-07-29
CL2011000242A1 (es) 2011-04-08
WO2010017122A2 (fr) 2010-02-11
NI201100031A (es) 2011-09-26
AU2009279825A1 (en) 2010-02-11
SV2011003823A (es) 2011-08-15
CA2732791A1 (fr) 2010-02-11
KR20110053347A (ko) 2011-05-20
MX2011001426A (es) 2011-03-21
US20110269721A1 (en) 2011-11-03
EP2355827A2 (fr) 2011-08-17
CN102112131A (zh) 2011-06-29
DOP2011000044A (es) 2011-04-30
CO6351728A2 (es) 2011-12-20
BRPI0917575A2 (pt) 2019-09-24
JP2011530517A (ja) 2011-12-22
RU2011108563A (ru) 2012-09-10
CR20110115A (es) 2011-06-03

Similar Documents

Publication Publication Date Title
MA32611B1 (fr) Procedes de traitement de la thalassemie
NZ599906A (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA200971053A1 (ru) Способы лечения кожных язв
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
WO2011053822A3 (fr) Inhibition de notch pour le traitement et la prévention de l'obésité et du syndrome métabolique
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
EA201391591A1 (ru) Лечение множественной миеломы
EA201100255A1 (ru) 5-алкинилпиримидины
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
UA107562C2 (uk) Спосіб лікування псоріазу
EA201001749A1 (ru) Способ лечения недифференцированного артрита
EA200970436A1 (ru) Соединения карбамата для лечения депрессии